A. Menarini Industrie Farmaceutiche Riunite Srl - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH37399D
- Pages: 54
- November 2018
- Total Views:1179
- Region : Europe
- GlobalData
- Equity Research Report
Details
Summary
A. Menarini Industrie Farmaceutiche Riunite Srl (Menarini), formerly Farmacia Internazionale, is a biopharmaceutical company that undertakes the research, development and manufacture of several pharmaceutical products in various dosage forms. The company's products portfolio is focused on a several therapeutic and wellness areas including allergy, andrology, antinfective areas, cardiovascular areas, gastrointestinal disorders, gynecology and women's wellness, respiratory areas, rheumatology, osteoporosis, dermatology and personal care, energy supplements and multivitamins, and others. Menarini operates through its manufacturing sites, research and development centers and has presence across Europe and Asia, Africa, Central and South America. It distributes products across several countries worldwide through partners and distributors. Menarini is headquartered in Florence, Italy.
A. Menarini Industrie Farmaceutiche Riunite Srl-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
A. Menarini Industrie Farmaceutiche Riunite Srl, Medical Devices Deals, 2012 to YTD 2018 10
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
Menarini Raunaq Pharma Plans To Acquire Pharma Brands In India For USD 80 Million 14
Partnerships 15
Melinta Therapeutics Enters into Agreement with Menarini 15
Orion Enters into Co-Marketing Agreement with A. Menarini Industrie Farmaceutiche Riunite 16
Menarini Asia-Pacific Enters into Agreement with Merck 17
Menarini Forms Joint Venture with BiosYnth 18
Moberg Extends Distribution Agreement with Menarini for Emtrix 19
Moberg Pharma Extends Distribution Agreement with Berlin-Chemie for Emtrix 20
Moberg Pharma Extends Distribution Agreement With Menarini 21
Moberg Extends Distribution Agreement With Menarini For Kerasal Nail 22
Menarini Enters Into Commercialization Agreement With Gilead Sciences For Ranexa 23
Menarini Enters Into Agreement With Oxford BioTherapeutics To Develop Antibody-Based Anticancer Drugs 24
Teijin Pharma Extends Co-Marketing Agreement With Menarini For TMX-67 25
Licensing Agreements 26
Menarini Enters into Licensing Agreement with Melinta Therapeutics 26
Menarini Enters into Licensing Agreement with Daiichi Sankyo 27
Berlin-Chemie Enters into Licensing Agreement with Selvita 28
Berlin-Chemie Enters into Licensing Agreement with Chugai Pharma 29
Menarini Enters into Licensing Agreement with Mitsubishi Tanabe Pharma for Spedra 30
Menarini Enters into Licensing and Development Agreement with 4SC for Resminostat 31
Vivus Enters Into Licensing Agreement With Menarini For Spedra 32
Furiex Pharma Enters Into Licensing Agreement With Menarini Group For Priligy 34
A. Menarini Industrie Farmaceutiche Riunite Enters into Licensing Agreement with Orion 35
Sinclair IS Pharma Enters Into Licensing Agreement With Menarini Group For Three Products 36
FAES Farma Enters into License Agreement with Menarini For Bilastina 37
Almirall Enters Into Licensing Agreement With Invida For Aclidinium 38
Faes Farma And Invida Enter Into Licensing Agreement For Bilastine 40
Almirall Enters Into Licensing Agreement With Menarini Biotech For Aclidinium Bromide 41
Acquisition 42
Menarini Group Plans To Acquire Indian Pharma Company 42
A. Menarini Industrie Farmaceutiche Riunite Srl-Key Competitors 43
A. Menarini Industrie Farmaceutiche Riunite Srl-Key Employees 44
A. Menarini Industrie Farmaceutiche Riunite Srl-Locations And Subsidiaries 45
Head Office 45
Other Locations & Subsidiaries 45
Joint Venture 48
Recent Developments 49
Strategy And Business Planning 49
Mar 13, 2017: Menarini Arrives In Columbia And Peru Two New Offices For A Stronger Connection Between Two Continents 49
Jan 18, 2017: Menarini In Turkey: +25% Growth In 2016 And New Headquarters In Istanbul 50
Corporate Communications 51
Jun 29, 2017: Menarini Increases Number of Members of the Board-for the First Time External Members In Majority 51
Product News 52
Apr 12, 2017: Menarini Brings Sirmione Thermal Water Into Italian Homes 52
03/17/2017: Selvita Announces First Patient Dosed in Phase I/II Clinical Trial of SEL24 in Acute Myeloid Leukemia 53
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54
List Of Figure
List of Figures
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
A. Menarini Industrie Farmaceutiche Riunite Srl, Medical Devices Deals, 2012 to YTD 2018 10
List Of Table
List of Tables
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Key Facts, 2017 2
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
A. Menarini Industrie Farmaceutiche Riunite Srl, Deals By Therapy Area, 2012 to YTD 2018 9
A. Menarini Industrie Farmaceutiche Riunite Srl, Medical Devices Deals, 2012 to YTD 2018 10
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Menarini Raunaq Pharma Plans To Acquire Pharma Brands In India For USD 80 Million 14
Melinta Therapeutics Enters into Agreement with Menarini 15
Orion Enters into Co-Marketing Agreement with A. Menarini Industrie Farmaceutiche Riunite 16
Menarini Asia-Pacific Enters into Agreement with Merck 17
Menarini Forms Joint Venture with BiosYnth 18
Moberg Extends Distribution Agreement with Menarini for Emtrix 19
Moberg Pharma Extends Distribution Agreement with Berlin-Chemie for Emtrix 20
Moberg Pharma Extends Distribution Agreement With Menarini 21
Moberg Extends Distribution Agreement With Menarini For Kerasal Nail 22
Menarini Enters Into Commercialization Agreement With Gilead Sciences For Ranexa 23
Menarini Enters Into Agreement With Oxford BioTherapeutics To Develop Antibody-Based Anticancer Drugs 24
Teijin Pharma Extends Co-Marketing Agreement With Menarini For TMX-67 25
Menarini Enters into Licensing Agreement with Melinta Therapeutics 26
Menarini Enters into Licensing Agreement with Daiichi Sankyo 27
Berlin-Chemie Enters into Licensing Agreement with Selvita 28
Berlin-Chemie Enters into Licensing Agreement with Chugai Pharma 29
Menarini Enters into Licensing Agreement with Mitsubishi Tanabe Pharma for Spedra 30
Menarini Enters into Licensing and Development Agreement with 4SC for Resminostat 31
Vivus Enters Into Licensing Agreement With Menarini For Spedra 32
Furiex Pharma Enters Into Licensing Agreement With Menarini Group For Priligy 34
A. Menarini Industrie Farmaceutiche Riunite Enters into Licensing Agreement with Orion 35
Sinclair IS Pharma Enters Into Licensing Agreement With Menarini Group For Three Products 36
FAES Farma Enters into License Agreement with Menarini For Bilastina 37
Almirall Enters Into Licensing Agreement With Invida For Aclidinium 38
Faes Farma And Invida Enter Into Licensing Agreement For Bilastine 40
Almirall Enters Into Licensing Agreement With Menarini Biotech For Aclidinium Bromide 41
Menarini Group Plans To Acquire Indian Pharma Company 42
A. Menarini Industrie Farmaceutiche Riunite Srl, Key Competitors 43
A. Menarini Industrie Farmaceutiche Riunite Srl, Key Employees 44
A. Menarini Industrie Farmaceutiche Riunite Srl, Subsidiaries 45
A. Menarini Industrie Farmaceutiche Riunite Srl, Joint Venture 48
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Company Profile
Company Profile Title
Summary
A. Menarini Industrie Farmaceutiche Riunite Srl (Menarini), formerly Farmacia Internazionale, is a biopharmaceutical company that undertakes the research, development and manufacture of several pharmaceutical products in various dosage forms. The company's products portfolio is focused on a several therapeutic and wellness areas including allergy, andrology, antinfective areas, cardiovascular areas, gastrointestinal disorders, gynecology and women's wellness, respiratory areas, rheumatology, osteoporosis, dermatology and personal care, energy supplements and multivitamins, and others. Menarini operates through its manufacturing sites, research and development centers and has presence across Europe and Asia, Africa, Central and South America. It distributes products across several countries worldwide through partners and distributors. Menarini is headquartered in Florence, Italy.
A. Menarini Industrie Farmaceutiche Riunite Srl-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
A. Menarini Industrie Farmaceutiche Riunite Srl, Medical Devices Deals, 2012 to YTD 2018 10
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
Menarini Raunaq Pharma Plans To Acquire Pharma Brands In India For USD 80 Million 14
Partnerships 15
Melinta Therapeutics Enters into Agreement with Menarini 15
Orion Enters into Co-Marketing Agreement with A. Menarini Industrie Farmaceutiche Riunite 16
Menarini Asia-Pacific Enters into Agreement with Merck 17
Menarini Forms Joint Venture with BiosYnth 18
Moberg Extends Distribution Agreement with Menarini for Emtrix 19
Moberg Pharma Extends Distribution Agreement with Berlin-Chemie for Emtrix 20
Moberg Pharma Extends Distribution Agreement With Menarini 21
Moberg Extends Distribution Agreement With Menarini For Kerasal Nail 22
Menarini Enters Into Commercialization Agreement With Gilead Sciences For Ranexa 23
Menarini Enters Into Agreement With Oxford BioTherapeutics To Develop Antibody-Based Anticancer Drugs 24
Teijin Pharma Extends Co-Marketing Agreement With Menarini For TMX-67 25
Licensing Agreements 26
Menarini Enters into Licensing Agreement with Melinta Therapeutics 26
Menarini Enters into Licensing Agreement with Daiichi Sankyo 27
Berlin-Chemie Enters into Licensing Agreement with Selvita 28
Berlin-Chemie Enters into Licensing Agreement with Chugai Pharma 29
Menarini Enters into Licensing Agreement with Mitsubishi Tanabe Pharma for Spedra 30
Menarini Enters into Licensing and Development Agreement with 4SC for Resminostat 31
Vivus Enters Into Licensing Agreement With Menarini For Spedra 32
Furiex Pharma Enters Into Licensing Agreement With Menarini Group For Priligy 34
A. Menarini Industrie Farmaceutiche Riunite Enters into Licensing Agreement with Orion 35
Sinclair IS Pharma Enters Into Licensing Agreement With Menarini Group For Three Products 36
FAES Farma Enters into License Agreement with Menarini For Bilastina 37
Almirall Enters Into Licensing Agreement With Invida For Aclidinium 38
Faes Farma And Invida Enter Into Licensing Agreement For Bilastine 40
Almirall Enters Into Licensing Agreement With Menarini Biotech For Aclidinium Bromide 41
Acquisition 42
Menarini Group Plans To Acquire Indian Pharma Company 42
A. Menarini Industrie Farmaceutiche Riunite Srl-Key Competitors 43
A. Menarini Industrie Farmaceutiche Riunite Srl-Key Employees 44
A. Menarini Industrie Farmaceutiche Riunite Srl-Locations And Subsidiaries 45
Head Office 45
Other Locations & Subsidiaries 45
Joint Venture 48
Recent Developments 49
Strategy And Business Planning 49
Mar 13, 2017: Menarini Arrives In Columbia And Peru Two New Offices For A Stronger Connection Between Two Continents 49
Jan 18, 2017: Menarini In Turkey: +25% Growth In 2016 And New Headquarters In Istanbul 50
Corporate Communications 51
Jun 29, 2017: Menarini Increases Number of Members of the Board-for the First Time External Members In Majority 51
Product News 52
Apr 12, 2017: Menarini Brings Sirmione Thermal Water Into Italian Homes 52
03/17/2017: Selvita Announces First Patient Dosed in Phase I/II Clinical Trial of SEL24 in Acute Myeloid Leukemia 53
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54
List Of Figure
List of Figures
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
A. Menarini Industrie Farmaceutiche Riunite Srl, Medical Devices Deals, 2012 to YTD 2018 10
List Of Table
List of Tables
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Key Facts, 2017 2
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
A. Menarini Industrie Farmaceutiche Riunite Srl, Deals By Therapy Area, 2012 to YTD 2018 9
A. Menarini Industrie Farmaceutiche Riunite Srl, Medical Devices Deals, 2012 to YTD 2018 10
A. Menarini Industrie Farmaceutiche Riunite Srl, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Menarini Raunaq Pharma Plans To Acquire Pharma Brands In India For USD 80 Million 14
Melinta Therapeutics Enters into Agreement with Menarini 15
Orion Enters into Co-Marketing Agreement with A. Menarini Industrie Farmaceutiche Riunite 16
Menarini Asia-Pacific Enters into Agreement with Merck 17
Menarini Forms Joint Venture with BiosYnth 18
Moberg Extends Distribution Agreement with Menarini for Emtrix 19
Moberg Pharma Extends Distribution Agreement with Berlin-Chemie for Emtrix 20
Moberg Pharma Extends Distribution Agreement With Menarini 21
Moberg Extends Distribution Agreement With Menarini For Kerasal Nail 22
Menarini Enters Into Commercialization Agreement With Gilead Sciences For Ranexa 23
Menarini Enters Into Agreement With Oxford BioTherapeutics To Develop Antibody-Based Anticancer Drugs 24
Teijin Pharma Extends Co-Marketing Agreement With Menarini For TMX-67 25
Menarini Enters into Licensing Agreement with Melinta Therapeutics 26
Menarini Enters into Licensing Agreement with Daiichi Sankyo 27
Berlin-Chemie Enters into Licensing Agreement with Selvita 28
Berlin-Chemie Enters into Licensing Agreement with Chugai Pharma 29
Menarini Enters into Licensing Agreement with Mitsubishi Tanabe Pharma for Spedra 30
Menarini Enters into Licensing and Development Agreement with 4SC for Resminostat 31
Vivus Enters Into Licensing Agreement With Menarini For Spedra 32
Furiex Pharma Enters Into Licensing Agreement With Menarini Group For Priligy 34
A. Menarini Industrie Farmaceutiche Riunite Enters into Licensing Agreement with Orion 35
Sinclair IS Pharma Enters Into Licensing Agreement With Menarini Group For Three Products 36
FAES Farma Enters into License Agreement with Menarini For Bilastina 37
Almirall Enters Into Licensing Agreement With Invida For Aclidinium 38
Faes Farma And Invida Enter Into Licensing Agreement For Bilastine 40
Almirall Enters Into Licensing Agreement With Menarini Biotech For Aclidinium Bromide 41
Menarini Group Plans To Acquire Indian Pharma Company 42
A. Menarini Industrie Farmaceutiche Riunite Srl, Key Competitors 43
A. Menarini Industrie Farmaceutiche Riunite Srl, Key Employees 44
A. Menarini Industrie Farmaceutiche Riunite Srl, Subsidiaries 45
A. Menarini Industrie Farmaceutiche Riunite Srl, Joint Venture 48
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Ask A Question
Our Team Will Assist You in What You Are Looking For
or 
: +91 98100 26150
: ankurgupta1984
Related Reports
Page 130 | 
December 2020
Page 130 | December 2020
Page 131 | November 2020
Page 95 | November 2020
Page 96 | August 2020